Aerie Pharma (AERI) Misses Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aerie Pharma (AERI) PT Lowered to $22 at Needham & Company
November 5, 2021 7:29 AM EDTNeedham & Company analyst Serge Belanger lowered the price target on Aerie Pharma (NASDAQ: AERI) to $22.00 (from $24.00) while maintaining a Buy rating.
The analyst commented, "AERI's glaucoma franchise met expectations with 3Q21 sales of $29.3MM (+46%Y/Y and +8%Q/Q). The co. remains comfortable... More
